Pembrolizumab in Progressive Multifocal Leukoencephalopathy (PML) in Immunocompromised Patients Without HIV Infection

NCT06276504 · clinicaltrials.gov ↗

PHASE2,PHASE3

Phase

NOT_YET_RECRUITING

Status

33

Enrollment

OTHER

Sponsor class

Conditions

Progressive Multifocal Leukoencephalopathy

Interventions

DRUG: Pembrolizumab, 25 mg/ml solution for intravenous (IV) injection

Sponsor

Assistance Publique - Hôpitaux de Paris